EUCTR2018-000261-36-IT进行中（未招募）1 期
MULTICENTRE, OPEN-LABEL, UNCONTROLLED, PIVOTAL CLINICAL TRIAL TO CONFIRM THE EFFICACY AND SAFETY OF AUTOLOGOUS FIBRIN-CULTURED EPIDERMAL GRAFTS CONTAINING EPIDERMAL STEM CELLS GENETICALLY MODIFIED FOR RESTORATION OF EPIDERMIS IN PATIENTS WITH JUNCTIONAL EPIDERMOLYSIS BULLOSA (HOLOGENE 5) - Hologene 5
HOLOSTEM TERAPIE AVANZATE S.R.L.0 个研究点目标入组 6 人开始时间: 2020年10月7日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must meet all of the following inclusion criteria:
- •1.Signed and dated informed consent prior to any study-related procedures;
- •2.Male and female patients between 6-month-old and 55-year-old;
- •3.Diagnosis of generalized intermediate LAMB3-dependent JEB, confirmed by NGS or Sanger sequencing and immunofluorescence;
- •4.Detectable residual expression of laminin 332 (and its beta3 chain) by immunofluorescence and/or Western analysis;
- •5.Presence of blisters and/or = 10 cm2 erosions (persistent or recurrent for more than 3 months);
- •6.A cooperative attitude to follow the study procedures (caregivers in case of children);
- •7.Patients’ compliance with the study schedule and procedures, including complete immobilization of the transplanted areas for at least two weeks and hospitalization up to 1 month after transplantation.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 2
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients must not meet all of the following exclusion criteria:
- •1.Known or suspected intolerance to anaesthesia;
- •2.Bad general condition (ECOG index >1);
- •3.Presence of Squamous Cell Carcinomas (SCCs) in the area(s) qualified for treatment;
- •4.Clinical and/or laboratory signs of acute systemic infections at the time of screening. Patient can be re-screened after appropriate treatment;
- •5.Female subjects: pregnant or lactating women and all women with childbearing potential unless they are willing to use one or more reliable methods of contraception with a Pearl index =1. Reliable contraception should be maintained throughout the study.
- •A pregnancy test will be performed at screening in all women of childbearing potential and repeated before biopsy treatment and at all visits. A pregnancy test will not be required for post-menopausal women (physiologic menopause defined as 12 consecutive months of amenorrhea”) or women permanently sterilized (e.g. tubal occlusion, hysterectomy or bilateral salpingectomy).
- •Parental control will be applied for the pediatric population when needed;
- •6.Allergy, sensitivity or intolerance to study medication excipients or other material required by study protocol (as per Investigator’s brochure):
- •-Transport medium (Dulbecco’s Modified Eagles Medium supplemented with L-glutamine)
- •-Fibrin support
- •-Povidone iodine or Prontosan® (or equivalent selected for the treatment in consultation with the Sponsor Medical Expert)
- •7.Contraindications to the local or systemic antibiotics and/or corticosteroids foreseen by the protocol;
- •8.Contraindications to undergo extensive surgical procedures;
- •9.Presence of i) systemic diseases, ii) clinically significant or unstable concurrent disease, iii) other concomitant medical conditions, iv) other clinical contraindications to stem cell transplantation, which based on Investigator’s judgment, in consultation with the Sponsor Medical Expert may affect the participation in the study or the grafting procedure;
- •10.Patients (or parents in case of paediatric subject) unlikely to comply with the study protocol or unable to understand the nature and scope of the study or the possible benefits or unwanted effects of the study procedures and treatments.
- •11.Previous treatments or participation in clinical trials envisaging the use of cells (including bone marrow transplantation, BMT) and/or both in vivo or ex vivo gene therapy products.
研究者
相似试验
已完成
3 期
CLINICAL TRIAL OF ELETRIPTAN TO TREAT ACUTE MIGRAINE ATTACKS IN ADULT PATIENTSCTRI/2010/091/000425Intas Pharmaceuticals Limited240
进行中（未招募）
1 期
This study examines the safety and efficacy of using ELAD treatment as a continuous liver support to a subject with liver failure secondary to acute hepatocellular insult and alcohol use, allowing time for the subject's native liver to recover and restore to a functional state. The study's primary objective is to evaluate ELAD safety and efficacy on overall survival through at least Study Day 91, with follow-up Protocol VTL-308E providing additional survival data up to a maximum of 5 years.EUCTR2015-004529-14-ESVital Therapies, Inc.150
已完成
4 期
Open-label, multi-center, uncontrolled, post-market clinical follow-up (PMCF) investigation to confirm effectiveness and safety of Belotero® Balance Lidocaine in the treatment of horizontal forehead linesHorizontal forehead lines (HFL)DRKS00031795Merz Aesthetics GmbH106
尚未招募
3 期
A clinical trial to assess the efficacy and safety of mycophenolate modified release tablets in the prophylaxis of acute rejection of renal transplantatioCTRI/2012/02/002444Panacea Biotec Ltd204
进行中（未招募）
不适用
A STUDY TO ASSESS SAFETY AND EFFICACY OF ELAD IN SUBJECTS WITH ALCOHOL-INDUCED LIVER DECOMPENSATION (AILD)EUCTR2012-005563-27-ESVITAL THERAPIES INCORPORATED200